The Peptide Receptor Radionuclide Therapy (PRRT) Industry is on a trajectory of exceptional growth, with projections indicating a worth of US$ 591.83 million in 2023 and a substantial leap towards US$ ...

The peptide receptor radionuclide therapy (PRRT) market is projected to be valued at approximately USD 591.83 million in 2023 and is expected to expand significantly, reaching USD 1,300 million by ...

Peptide receptor radionuclide therapy (PRRT) with lutetium dotatate is a treatment for well-differentiated neuroendocrine tumors that the U.S. Food and Drug Administration approved in 2018, but ...

Theranostics and radiopharmaceutical therapies are rapidly transforming the medical landscape, and the neuro-oncology ...

A simple blood draw can provide physicians with valuable information that can determine if peptide receptor radionuclide therapy (PRRT) is likely to be effective in a patient with neuroendocrine ...

Combination of ZG005 with etoposide and cisplatin (EP) vs. EP as the first-line therapy for advanced neuroendocrine carcinoma: A randomized, multicenter, phase I/II trial. This is an ASCO Meeting ...

Transaxial slices of baseline positron emission tomography (PET) and fused PET/magnetic resonance imaging (MRI; left) demonstrate a somatostatin receptor-expressing meningioma in the left cavernous ...

Patients with neuroendocrine tumors (NETs) may experience fewer symptoms and survive longer by undergoing peptide-receptor radionuclide therapy (PRRT) combined with a drug that makes tumor cells more ...

Since its approval in 2018 by the US Food and Drug Administration, peptide receptor radionuclide therapy (PRRT) has become a mainstay in the treatment of neuroendocrine tumors. Lutetium-177-DOTATATE, ...

Peptide receptor radionuclide therapy (PRRT) and lutetium dotatate are treatments for well-differentiated neuroendocrine tumors. Clinicians have lacked a metric for predicting its benefit on an ...